2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-151387
    A2AAR antagonist 1 1784491-64-0 98%
    A2AAR antagonist 1 (compound 21a) is an A2AAR (adenosine A2A receptor) antagonist with a Ki value of 20 nM. A2AAR antagonist 1 shows high ligand efficiency, and it can be used for the research of neurodegenerative diseases.
    A2AAR antagonist 1
  • HY-151542
    MLKL-IN-4 3031406-17-1 98%
    MLKL-IN-4 (compound 56) is a potent MLKL (Mixed lineage kinase domain-like protein) inhibitor. MLKL-IN-4 inhibits necroptosis in HT-29 cells and acts downstream of MLKL phosphorylation, with EC50 of 82 nM. MLKL-IN-4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    MLKL-IN-4
  • HY-15204S
    Tonabersat-d6 1329837-33-3 98%
    Tonabersat-d6 (SB-220453-d6) is deuterium labeled Tonabersat. Tonabersat (SB-220453) is a gap-junction modulator. Tonabersat prevents inflammatory damage in the central nervous system.
    Tonabersat-d6
  • HY-152171
    GZ-11608 2141974-01-6 98%
    GZ-11608 is a potent and selective vesicular monoamine transporter-2 (VMAT2) inhibitor with high affinity (Ki = 25 nM). GZ-11608 decreases methamphetamine-induced dopamine release from isolated synaptic vesicles from brain dopaminergic neurons. GZ-11608 exhibits rapid brain penetration and without neurotoxicity. GZ-11608 can be used for the research of methamphetamine use disorder.
    GZ-11608
  • HY-15250R
    JZL195 (Standard) 1210004-12-8 98%
    JZL195 (Standard) is the analytical standard of JZL195. This product is intended for research and analytical applications. JZL195 is a selective and efficacious dual fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibitor with IC50s of 2 and 4 nM, respectively.
    JZL195 (Standard)
  • HY-15257R
    Mavoglurant (Standard) 543906-09-8 98%
    Mavoglurant (Standard) is the analytical standard of Mavoglurant. This product is intended for research and analytical applications. Mavoglurant (AFQ056) is a potent, selective, non-competitive and orally active mGluR5 antagonist, with an IC50 of 30 nM. Mavoglurant shows a >300 fold selectivity for the mGluR5 over all targets (238) tested. Mavoglurant can be used for the research of Fragile X syndrome (FXS), and L-dopa induced dyskinesias in Parkinson's disease. Mavoglurant is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Mavoglurant (Standard)
  • HY-15289R
    Ciproxifan maleate (Standard) 184025-19-2 98%
    Ciproxifan (maleate) (Standard) is the analytical standard of Ciproxifan (maleate). This product is intended for research and analytical applications. Ciproxifan maleate (FUB 359 maleate) is a potent, selective, orally bioavailable and competitive antagonist of histamine H3-receptor, with an IC50 of 9.2 nM. Ciproxifan maleate displays low apparent affinity at other receptor subtypes. Ciproxifan maleate can be used for the research of aging disorders and Alzheimer's disease.
    Ciproxifan maleate (Standard)
  • HY-15394R
    (Rac)-Rotigotine hydrochloride (Standard) 102120-99-0 98%
    (Rac)-Rotigotine (hydrochloride) (Standard) is the analytical standard of (Rac)-Rotigotine (hydrochloride). This product is intended for research and analytical applications. (Rac)-Rotigotine hydrochloride is a racemate of Rotigotine. Rotigotine is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor, with Kis of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.
    (Rac)-Rotigotine hydrochloride (Standard)
  • HY-15401A
    WAY 163909 (hydrochloride) 428868-35-3 98%
    WAY 163909 hydrochloride is an orally active, blood-brain barrier permeable 5-HT2C receptor-selective agonist. WAY 163909 hydrochloride exhibits an EC50 of 8 nM and a Ki of 10.5 nM for h5-HT2C. Instead of triggering apoptosis, WAY 163909 hydrochloride induces anorectic, antipsychotic-like, antidepressant-like, anti-aggressive and anti-compulsive effects. WAY 163909 hydrochloride alleviates ketamine-induced hypothermia, but impairs sexual function at high doses. With rapid antidepressant-like properties, WAY 163909 hydrochloride can be used in research related to obesity, schizophrenia, depression, obsessive-compulsive disorder, and anesthesia-induced hypothermia.
    WAY 163909 (hydrochloride)
  • HY-15443R
    AM251 (Standard) 183232-66-8 98%
    AM251 (Standard) is the analytical standard of AM251. This product is intended for research and analytical applications. AM251 is a selective cannabinoid 1 (CB1) receptor antagonist with an IC50 of 8 nM. AM251 also acts as a potent GPR55 agonist with an EC50 of 39 nM.
    AM251 (Standard)
  • HY-15446R
    Basimglurant (Standard) 802906-73-6
    Basimglurant (RG7090; RO4917523) (Standard) is the analytical standard of Basimglurant. This product is intended for research and analytical applications. Basimglurant is a selective, orally active, blood-brain barrier permeable negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5), with a Ki of 1.4 nM (against [3H]-ABP688 (HY-110141)) and 35.6 nM (against [3H]-MPEP (HY-14609A)). Basimglurant inhibits mGlu5-mediated signaling pathways and receptor constitutive activity, regulates dopamine levels in the nucleus accumbens, exerts anxiolytic, antidepressant-like, analgesic and arousal-promoting effects, and alters δ-wave power during non-rapid eye movement sleep. Basimglurant can be used in research on depression, fragile X syndrome, anxiety disorders, etc.
    Basimglurant (Standard)
  • HY-15451R
    MDA 19 (Standard) 1048973-47-2 98%
    MDA 19 (Standard) is the analytical standard of MDA 19. This product is intended for research and analytical applications. MDA 19 is a potent and selective agonist of human cannabinoid receptor 2 (CB2), with a Ki of 43.3 nM. MDA 19 has antiallodynic effects in a rat model of neuropathic pain and does not affect rat locomotor activity.
    MDA 19 (Standard)
  • HY-15488R
    A 438079 (Standard) 899507-36-9 98%
    A 438079 (Standard) is the analytical standard of A 438079. This product is intended for research and analytical applications. A 438079 is a potent, and selective P2X7 receptor antagonist with pIC50 of 6.9.
    A 438079 (Standard)
  • HY-15527R
    Emapunil (Standard) 226954-04-7 98%
    Emapunil (Standard) is the analytical standard of Emapunil. This product is intended for research and analytical applications. Emapunil (AC-5216), an orally active and selective TSPO (a mitochondrial benzodiazepine receptor) ligand, produces anti-anxiety and antidepressant-like effects in various animal models.
    Emapunil (Standard)
  • HY-155450
    GK81 250682-96-3 98%
    GK81 is a nicotine hapten. GK81 contains a linker attached to the 6-position of nicotine. GK81 conjugates to KLH via carbodiimide-mediated reactions.
    GK81
  • HY-155466
    Boc-MIF-1-Am 3056144-84-1 98%
    Boc-MIF-1-Am (compound 2) is a human dopamine D2 receptor enhancer (EC50=17.82 nM) and is a bioconjugate of melanostatin (MIF-1) and amantadine. Boc-MIF-1-Am (200 μM) exhibited mild neurotoxicity in SH-SY5Y cells.
    Boc-MIF-1-Am
  • HY-155941
    5-Hydroxydecanoic acid 624-00-0 98%
    5-Hydroxydecanoic acid (5-HD） is a KATP channel antagonist，which has the effect of blocking the K KATP channel only during ischaemia by competing with the ATP binding site and does not affect pancreatic KATP channels.
    5-Hydroxydecanoic acid
  • HY-15600B
    UPF-648 sodium salt 1465017-87-1 98%
    UPF-648 sodium salt is an effective inhibitor of kynurenine 3-monooxygenase (KMO), achieving approximately 81% inhibition at a concentration of 1uM, with no inhibitory effect on kynurenine aminotransferase (KAT).
    UPF-648 sodium salt
  • HY-156022
    Antitubercular agent-41 901032-23-3 99.69%
    Antitubercular agent-41 (Compound 106) is an antitubercular agent that can be used in the study of Mycobacterium tuberculosis infection.
    Antitubercular agent-41
  • HY-156069
    Methylspinazarin 41768-12-1 98%
    Methylspinazarin is a potent inhibitor of catechol O-methyltransferase (COMT, IC50 = 0.8 μg/ml) that can be isolated from Streptomyces. Methylspinazarin is selective for COMT over tyrosine hydroxylase.
    Methylspinazarin
Cat. No. Product Name / Synonyms Application Reactivity